Folinic acid vs placebo in young children with autism
Official title: A Placebo-Controlled, Randomized, Double-Blind Study to Assess the Safety, Tolerability and Efficacy of Folinic Acid Administered to Pediatric Subjects With Autism Spectrum Disorder (ASD)
Run by Shaare Zedek Medical Center · NCT07642661 · Data updated 2026-11-12
This trial tests whether folinic acid can help improve communication and behavior in children with autism aged 3 to 6 years who have not been diagnosed with a known genetic syndrome.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 3 Years to 6 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Shaare Zedek Medical Center Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Jerusalem, N/A = Not Applicable) |
| Status | Recruiting |
| Started | June 23, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT07642661 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children ages 3-6 with non-syndromic ASD, a confirmed diagnosis, and moderate symptom severity who meet weight and clinical criteria.
✕Probably not a fit
Children with comorbid conditions, recent seizure activity, or prior folinic acid exposure may be less likely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 2, randomized, placebo-controlled study evaluating folinic acid in children with autism spectrum disorder. Eligible participants are 3 to 6 years old with a DSM-5 ASD diagnosis confirmed by ADOS-2, who are non-syndromic and meet certain severity criteria. Participants are assigned to receive either folinic acid or placebo to determine its effects on core and associated symptoms. Outcomes focus on communication, social functioning, and behavior, with careful monitoring for safety and tolerability. The study is led by Prof. Adi Aran and conducted at Shaare Zedek Medical Center in Jerusalem.
Why it matters
Potential benefit: If successful, children may show improved communication and social skills, with potential reductions in behavioral symptoms.
How similar studies have gone: Prior small studies suggested possible benefits of folinic acid in ASD but evidence is not yet conclusive, making this a somewhat novel but exploratory trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children aged 3 to 6 years. * Diagnosis of autism spectrum disorder (ASD) according to DSM-5 criteria. * ASD diagnosis confirmed by Autism Diagnostic Observation Schedule, Second Edition (ADOS-2). * ASD diagnosis made at least 6 months before screening. * Non-syndromic ASD, defined as ASD occurring in the absence of a known genetic syndrome, chromosomal abnormality, major congenital anomaly, or identifiable metabolic or neurological disorder. * CGI-S score ≥ 4. * ABC-I score ≥ 12. * SRS-2 total T-score ≥ 66. * Body weight between 11.45 kg and \<27 kg. Exclusion Criteria: * A seizure or a change in antiepileptic medication within 8 weeks prior to randomization. * Clinically significant abnormalities on physical examination or laboratory testing, including significant impairment of cardiac, hepatic, or renal function. * Treatment with folinic acid within 3 months prior to randomization. * Any change in pharmacological treatment, behavioral treatment, home environment, or school setting (other than school holidays) within 4 weeks prior to randomization, or planned changes during study participation. * Predicted inability or unwillingness to comply with study procedures. * Use of antifolate medications or other agents known to interfere with folate metabolism (e.g., methotrexate, trimethoprim).
Where it's running
-
Shaare Zedek Medical Center
Jerusalem, N/A = Not Applicable, Israel Recruiting
Study contacts
- Study coordinator: Adi Aran, MD
- Email: aaran@szmc.org.il
- Phone: +97226555414
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sensory Integration and Deep Pressure Therapy for Motor Coordination in Children with ASD
This study tests whether combining Sensory Integration Therapy with Deep Pressure Therapy can improve motor coordination and reduce repetitive behaviors in children aged 4–10 with autism.
-
Pupillometer screen to help identify autism in kids aged 2–4 during routine visits
A handheld pupillometer test is being tried to see if it can help identify autism in young children during regular pediatric visits.
-
Leopard: using multi-omics to boost genetic diagnosis for neurodevelopmental disorders
This study tests a multi-omics approach to find genetic explanations for neurodevelopmental disorders in people with moderate-to-severe intellectual disability.
-
Heart Rate Variability Biofeedback for Anxiety in Autistic Youth
This study tests a wearable heart rate variability biofeedback tool to see if it helps reduce anxiety in autistic teens.
-
Structured Sensory-Based Occupational Therapy for Children with Autism
This study tests a 12-week, 40-minute sensory-based occupational therapy program twice a week to see if it improves daily skills, sensory processing, movement, and eating in children aged 3-9 with autism.
-
Exergaming and Aerobic Exercise for Kids with Autism
This study tests whether adding exergames or aerobic exercise to a standard program helps improve sleep, movement skills, thinking skills, and brain activity in children with autism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.